Johnson & Johnson Total Assets 2011-2025 | JNJ
Johnson & Johnson total assets from 2011 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Johnson & Johnson total assets for the quarter ending September 30, 2025 were $192.816B, a 8.15% increase year-over-year.
- Johnson & Johnson total assets for 2024 were $180.104B, a 7.49% increase from 2023.
- Johnson & Johnson total assets for 2023 were $167.558B, a 10.58% decline from 2022.
- Johnson & Johnson total assets for 2022 were $187.378B, a 2.94% increase from 2021.
|
Johnson & Johnson Annual Total Assets (Millions of US $) |
|
|---|---|
| 2024 | $180,104 |
| 2023 | $167,558 |
| 2022 | $187,378 |
| 2021 | $182,018 |
| 2020 | $174,894 |
| 2019 | $157,728 |
| 2018 | $152,954 |
| 2017 | $157,303 |
| 2016 | $141,208 |
| 2015 | $133,411 |
| 2014 | $130,358 |
| 2013 | $132,683 |
| 2012 | $121,347 |
| 2011 | $113,644 |
| 2010 | $102,908 |
|
Johnson & Johnson Quarterly Total Assets (Millions of US $) |
|
|---|---|
| 2025-09-30 | $192,816 |
| 2025-06-30 | $193,389 |
| 2025-03-31 | $193,671 |
| 2024-12-31 | $180,104 |
| 2024-09-30 | $178,287 |
| 2024-06-30 | $181,088 |
| 2024-03-31 | $171,966 |
| 2023-12-31 | $167,558 |
| 2023-09-30 | $166,061 |
| 2023-06-30 | $191,686 |
| 2023-03-31 | $195,969 |
| 2022-12-31 | $187,378 |
| 2022-09-30 | $175,124 |
| 2022-06-30 | $177,724 |
| 2022-03-31 | $178,355 |
| 2021-12-31 | $182,018 |
| 2021-09-30 | $179,228 |
| 2021-06-30 | $176,440 |
| 2021-03-31 | $172,557 |
| 2020-12-31 | $174,894 |
| 2020-09-30 | $170,693 |
| 2020-06-30 | $158,380 |
| 2020-03-31 | $155,017 |
| 2019-12-31 | $157,728 |
| 2019-09-30 | $155,521 |
| 2019-06-30 | $155,117 |
| 2019-03-31 | $150,027 |
| 2018-12-31 | $152,954 |
| 2018-09-30 | $155,703 |
| 2018-06-30 | $155,365 |
| 2018-03-31 | $156,625 |
| 2017-12-31 | $157,303 |
| 2017-09-30 | $155,658 |
| 2017-06-30 | $152,807 |
| 2017-03-31 | $144,918 |
| 2016-12-31 | $141,208 |
| 2016-09-30 | $140,369 |
| 2016-06-30 | $139,814 |
| 2016-03-31 | $136,231 |
| 2015-12-31 | $133,411 |
| 2015-09-30 | $133,266 |
| 2015-06-30 | $132,036 |
| 2015-03-31 | $128,590 |
| 2014-12-31 | $130,358 |
| 2014-09-30 | $132,097 |
| 2014-06-30 | $135,200 |
| 2014-03-31 | $133,330 |
| 2013-12-31 | $132,683 |
| 2013-09-30 | $126,933 |
| 2013-06-30 | $124,325 |
| 2013-03-31 | $121,536 |
| 2012-12-31 | $121,347 |
| 2012-09-30 | $118,951 |
| 2012-06-30 | $115,750 |
| 2012-03-31 | $116,194 |
| 2011-12-31 | $113,644 |
| 2011-09-30 | $111,821 |
| 2011-06-30 | $112,114 |
| 2011-03-31 | $108,150 |
| 2010-12-31 | $102,908 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $449.502B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $873.885B | 42.04 |
| AbbVie (ABBV) | United States | $387.340B | 23.19 |
| Roche Holding AG (RHHBY) | Switzerland | $267.000B | 0.00 |
| Novartis AG (NVS) | Switzerland | $266.905B | 14.15 |
| Merck (MRK) | United States | $214.149B | 9.97 |
| Novo Nordisk (NVO) | Denmark | $203.961B | 11.96 |
| Pfizer (PFE) | United States | $138.902B | 7.63 |
| Sanofi (SNY) | France | $121.941B | 11.71 |
| Bayer (BAYRY) | Germany | $29.748B | 5.61 |
| Innoviva (INVA) | United States | $1.315B | 7.81 |